Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 3Mesothelioma, Malignant 3Solid Tumors 2Neoplasm Metastasis 2Disease Progression 2Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × tumor necrosis factor-alpha, CNGRC fusion protein, human × Clear all
NCT03804866 2019-01-15

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

AGC Biologics S.p.A.

Phase 2 Completed
14 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

NCT00484432 2018-09-27

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

AGC Biologics S.p.A.

Phase 2 Completed
37 enrolled
Gynecologic

Ovarian Neoplasms

NCT01358071 2018-09-27

NGR018

AGC Biologics S.p.A.

Phase 2 Completed
119 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡